Answers are grounded in this paper and cite their sources.
Identifying endogenous suppressors targeting hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) will open new avenues for therapeutic options. Here, circRNome and transcriptome analyses were used to identify circRNAs in human HBV-HCC tissues. The role of circM-TMEFF1 was assessed both in vitro and in vivo . circM-TMEFF1 was inversely related to HBV replication and HCC progression and was identified as inhibiting the proliferation, colony formation, and migration of HCC cells and xenograft growth in a mouse model. HBV, IL-1β, and TNF-α up-regulated circM-TMEFF1 expression via trans -activating transcription factors MAFF and MAFK in HCC cells. circM-TMEFF1 sponged let-7e-5p that predominantly targeted deubiquitylase YOD1. circM-TMEFF1 or YOD1 significantly inhibited HBV replication and reservoir, especially for HBV with cancer-promoting mutations in the X gene. circM-TMEFF1/let-7e-5p/YOD1 axis inhibited STAT3 via YOD1 and NF-κB pathway by stabilizing IκBα. Conclusively, circM-TMEFF1 emerges as the first identified circRNA that inhibits HBV and HCC by inhibiting the NF-κB and STAT3 pathways via the circM-TMEFF1/let-7e-5p/YOD1 axis, making circM-TMEFF1 a promising new candidate for treating HBV-related HCC.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: